Assessment of in silico models for fraction of unbound drug in human liver microsomes

Bibliography

• Lipinski CA. Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. J Pharmacol Toxicol Methods 2000;44:235-49
   PubMed Web of Science ®Google Scholar
• Clark DE, Pickett SD. Computational methods for the prediction of “Drug-Likeness”. Drug Discov Today 2000;5:49-58
   PubMed Web of Science ®Google Scholar
• Walters WP. Murcko MA. Prediction of “Drug-Likeness”. Adv Drug Delivery Rev 2002;54:255-71
   PubMed Web of Science ®Google Scholar
• Lin J, Sahakian DC, de Morais SM, The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003;3:1125-54
   PubMed Web of Science ®Google Scholar
• Wagner JG, Northam JI, Alway CD, Carpenter OS. Blood levels of drug at the equilibrium state after multiple dosing. Nature 1968;207:1301-02
   Google Scholar
• Gao H, Yao Y, Mathieu HW, In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 2008;36:2130-35
   PubMed Web of Science ®Google Scholar
• Gillette J. Drug metabolism by enzyme mechanisms. Prog Drug Res 1963;6:55-7
   Google Scholar
• Kalvass JC, Tess DA, Giragossian C, Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 2001;29:1332-36
   PubMed Web of Science ®Google Scholar
• Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003;31:606-11
   PubMed Web of Science ®Google Scholar
• Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 1997;25:1359-69
   PubMed Web of Science ®Google Scholar
• Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-59
   PubMed Web of Science ®Google Scholar
• Tran TH, Von Moltke LL, Venkatakrishnan K, Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002;30:1441-45
   PubMed Web of Science ®Google Scholar
• Obach RS. The importance of nonspecific binding in vitro matrixes, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 1996;24:1047-49
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32
   PubMed Web of Science ®Google Scholar
• Grime K, Riley RJ. The impact of in vitro binding on in vitro – in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006;7:251-64
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–toward a consensus. Pharm Res 2001;18:1071-80
   PubMedGoogle Scholar
• Li H, Sun J, Sui X, Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes. AAPS J 2009;11:364-70
   PubMed Web of Science ®Google Scholar
• Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 2003;92:967-74
   PubMed Web of Science ®Google Scholar
• Giuliano C, Jairaj M, Zafiu CM, Laufer R. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos 2005;33:1319-24
   PubMed Web of Science ®Google Scholar
• Nakai D, Kumamoto K, Sakikawa C, Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 2004;93(4):847-54
   PubMed Web of Science ®Google Scholar
• Gao H, Shanmugasundaram V, Lee P. Estimation of aqueous solubility of organic compounds with QSPR approach. Pharm Res 2002;19(4):497-503
   PubMed Web of Science ®Google Scholar
• Selassie CD, DeSoyza TV, Rosario M, Phenol toxicity in leukemia cells: a radical process? Chem Biol Interact 1998;113(3):175-90
   PubMed Web of Science ®Google Scholar
• Koneru PB, Lien EJ, Koda RT. Oculotoxicities of systemically administered drugs. J Ocul Pharmacol 1986;2(4):385-404
   PubMedGoogle Scholar
• Ren S, Lien EJ. Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis. Prog Drug Res 2000;54:1-23
   PubMedGoogle Scholar
• Lien EJ, Gao H. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents. Pharm Res 1995;12(4):583-7
   PubMed Web of Science ®Google Scholar
• Lien EJ. Structure-activity relationships and drug disposition. Ann Rev Pharmacol Toxicol 1981;21:31-61
   PubMed Web of Science ®Google Scholar
• Lien EJ. Structure, properties and disposition of drugs. Prog Drug Res 1985;29:67-95
   PubMedGoogle Scholar
• Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A. Application of quantitative structure-activity relationships for modeling drug and chemical transport across the human placenta barrier: a multivariate data analysis approach. J Appl Toxicol 2009;29(8):724-33
   PubMed Web of Science ®Google Scholar
• Gao H, Hansch C. QSAR of p450 oxidation: on the value of comparing kcat and km with kcat/km. Drug Metab Rev 1996;28(4):513-26
   PubMed Web of Science ®Google Scholar
• Ren S, Das A, Lien EJ. QSAR analysis of membrane permeability to organic compounds. J Drug Target 1996;4(2):103-7
   PubMed Web of Science ®Google Scholar
• Li H, Sun J, Sui X, First-principle, structure-based prediction of hepatic metabolic clearance values in human. Eur J Med Chem 2009;44(4):1600-06
   PubMed Web of Science ®Google Scholar
• Nikolic K, Agababa D. Prediction of hepatic microsomal intrinsic clearance and human clearance values of drugs. J Mol Graph Model 2009;28(3):245-52
   PubMed Web of Science ®Google Scholar
• Lee PH, Cucurull-Sanchez L, Lu J, Du YJ. Development of in silico models for human liver microsomal stability. J Comput Aided Mol Des 2007; 21(12):665-73
   PubMed Web of Science ®Google Scholar
• Chen Y, Cameron K, Guzman-Perez A, Structure-pharmacokinetic relationship of in vivo rat biliary excretion. Biopharm Drug Dispos 2009. In press
   Web of Science ®Google Scholar
• Sun H, Scott DO. Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 2010;75(1):3-17
   PubMed Web of Science ®Google Scholar
• Fujita T, Hansch C. Analysis of the structure-activity relationship of the sulfonamide drugs using substituent constants. J Med Chem 1967;10(6):991-1000
   PubMed Web of Science ®Google Scholar
• Muir RM, Fujita T, Hansch C. Structure-activity relationship in the auxin activity of mono-substituted phenylacetic acids. Plant Physiol 1967;42(11):1519-26
   PubMed Web of Science ®Google Scholar
• Iwasa J, Fujita T, Hansch C. Substituent constants for aliphatic functions obtained from partition coefficients. J Med Chem 1965; 8:150-153
   PubMed Web of Science ®Google Scholar
• Hansch C, Hoekman D, Gao H. Comparative QSAR: toward a deeper understanding of chemicobiological interactions. Chem Rev 1996;96(3):1045-76
   PubMed Web of Science ®Google Scholar
• Gao H, Katzenellenbogen JA, Garg R, Hansch C. Comparative QSAR analysis of estrogen receptor ligands. Chem Rev 1999;99(3):723-44
   PubMed Web of Science ®Google Scholar
• McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000;49(5):453-61
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Cockroft SL, The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30(12):1497-03
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug. Metab. Dispos. 2006; 34(4):724-726
   PubMed Web of Science ®Google Scholar
• Turner DB, Rowland-Yeo K, Tucker GT, andRostami-Hodjegan A. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. Drug Metab Rev 2006;38(Suppl 1):162
   Google Scholar
• Sykes MJ, Sorich MG, Miners JO. Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 2006;46(6):2661-73
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 2008;36(7):1194-7
   PubMed Web of Science ®Google Scholar
• Gertz M, Kilford PJ, Houston JB, Galetin A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 2008;36(3):535-42
   PubMed Web of Science ®Google Scholar
• Austin RP, Davis AM, Manners CN. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J Pharm Sci 1995;84:1180-83
   PubMed Web of Science ®Google Scholar
• Krämer SD, Braun A, Jakits-Deiser C, Wunderli-Allenspach H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propranolol to phosphatidylinositol containing liposomes. Pharm Res 1998;15:739-44
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Riley RJ. Response to “Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement”. Drug Metab Dispos 2006;34(4):727
   Web of Science ®Google Scholar
• Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 2009;393:227-35
   Google Scholar
• ROCS, version 2.1.1. Openeye Scientific Software. Santa Fe, NM; 2005.
   Google Scholar
• Rulequest Research. 2006. Available from: www.rulequest.com
   Google Scholar
• De Buck SS, Sinha VK, Fenu LA, The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007;35:649-59
   PubMed Web of Science ®Google Scholar
• Fagerholm U. Prediction of human pharmacokinetics – evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 2007;59:803-28
   PubMed Web of Science ®Google Scholar
• Barre J, Chamouard JM, Houin G, Tlllement JP. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 1985;31(1):60-4
   PubMed Web of Science ®Google Scholar
• Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. J Med Chem 2007;50:101-12
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao L, Lin J, Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci 2010. In press
   Web of Science ®Google Scholar